Bone marrow transplantation with high‐dose cytosine arabinoside

R. H. Herzig, H. M. Lazarus, J. Graham‐Pole, S. Gross, P. Coccia, E. M. Gordon, S. Strandjord, G. L. Phillips, G. P. Herzig

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Eleven patients received allogeneic bone marrow from all HCA‐identical sibling for the treatment of acute leukemia. The preparative regiment included high‐dose cytosine arabinoside (Ara‐C), 3 g/m2q 12 h for 12 doses, and 1000 rad single‐fraction total body irradiation (5 patients) or 1200 rad fractionated total body irradiation (6 patients). The 5 patients receiving the 1000 rad single‐fraction regimen were transplanted in relapse, while the 6 patients receiving the 1200 rad fractionated program were transplanted during remission. Both regimens were well‐tolerated, but the single‐dose radiation regimen was associated with more severe skin problems. Bone marrow engraftment was documented in 10 of 10 evaluable patients, occurring 2‐3 weeks after marrow infusion. No recurrences have been observed during the brief follow‐up time.

Original languageEnglish (US)
Pages (from-to)235-238
Number of pages4
JournalMedical and Pediatric Oncology
Issue number1 S
StatePublished - 1982


  • acute leukemia
  • bone marrow transplantation
  • cytosine arabinoside

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research


Dive into the research topics of 'Bone marrow transplantation with high‐dose cytosine arabinoside'. Together they form a unique fingerprint.

Cite this